Biospecimen Core/Immunologic Monitoring and Cellular Products Laboratory

生物样本核心/免疫监测和细胞产品实验室

基本信息

批准号：
9091456
负责人：
Lisa Helene Butterfield
金额：
$ 40.63万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-26 至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/9091456
关键词：
Aftercare Antibody Response Antigens Autologous Autologous Dendritic Cells Biological Assay Biological Markers Biostatistics Core Blood Blood Banks Blood Vessels C-reactive protein CD14 gene CD3 Antigens CD4 Positive T Lymphocytes CD8 Antigens CD8B1 gene CTAG1 gene CXCL10 gene CXCL11 gene CXCL3 gene CXCL9 gene Cells Clinical Clinical Protocols Clinical Trials Communities Cyclic GMP Data Dendritic Cell Vaccine Eastern Cooperative Oncology Group Effector Cell Equipment and supply inventories Flow Cytometry Growth HLA-DR Antigens Helper-Inducer T-Lymphocyte IL2RA gene IL8 gene ITGAM gene Immune response Immunity Immunologic Monitoring Infiltration Informatics Interferon Alfa-2b Interferon Type II Interleukin-1 alpha Interleukin-10 Interleukin-17 Interleukin-2 Interleukin-6 Laboratories Leukapheresis Link Lymphoid Monophenol Monooxygenase Myelogenous NK Cell Activation Natural Killer Cells Outcome Patients Peptides Peripheral Blood Mononuclear Cell Process Production Protocols documentation Regulatory T-Lymphocyte Research SILV gene Sampling Serum Site Skin Cancer Suppressor-Effector T-Lymphocytes T cell response T-Lymphocyte TNF gene Testing Time Tissue Banking Tissue Banks Vaccine Antigen Vascular Endothelial Growth Factors chemokine cytokine enzyme linked immunospot assay melanoma monocyte programs response tumor

项目摘要

Core B serves the MSCP SPORE as the Biospecimen Core, as well as the Immunologic Monitoring and Cellular Products Laboratory (IMCPL). The laboratory supports the SPORE community with blood and tissue banking for patients submitting blood and/or tumor to the Melanoma Program tissue bank (#96-099), as well as ciinicai protocol-specific banking. For all of the projects proposed in this renewal, the Core wiil perform a wide variety of standardized, SOP-driven immunological monitoring assays. For Project 2, Core B will also prepare autologous dendritic cell vaccines. Core B will support each Project as follows: Project 1 (Tarhini/Storkus) Core B will support Project 1 Aims 1a and lb, testing circulating cellular and serum biomarkers from the trial ECOG 1609. Core B will assess host effector and suppressor cellular immune responses. We will perform multicolor flow cytometry to compare PBMC before and after treatment, focusing on circulating suppressor cells (Treg and MDSC) and antigen-specific effector and helper T cells, as well as serum biomarkers. Project 2 (Butterfield/Kirkwood): The Core will support Aim 1 (clinical trial #09-021) with autologous AdVTMM2-transduced dendritic cell vaccine manufacture, characterization and release for therapy. The Core will process all blood, leukapheresis and tumor samples and perform all banking For Aim 2, The Core will perform many standardized immune response assays. Project 3 (Zarour/Ferrone): The Core will support this Project with banking of PBMC and testing for activation and expansion of shared melanoma antigen-specific T cells. Project 4 (Falo/Geskin/Tawbi) Core B will perform the systemic immunologic monitoring proposed in Project 4 for both CTCL and melanoma patients. This will include serum, PBMC and tumor sample banking and testing, including innate and effector cell analysis. Together, the Biospecimen Core B will support the projects of the SPORE with tissue banking (all Projects), standardized immunologic monitoring (all Projects) and cGMP cellular product production for therapy (Project 2). Data generated in Core B will be analyzed in Biostatistics Core C and correlated to clinical parameters. The blood and tissue bank data and inventory are linked to the Clinical Trials Management Application and and will be part of the Research Data Warehouse developed by and managed in Informatics Core D.

核心 B 服务于 MSCP SPORE 作为生物样本核心，以及免疫监测和细胞产品实验室 (IMCPL)。该实验室支持 SPORE 社区，为向黑色素瘤计划组织库 (#96-099) 提交血液和/或肿瘤的患者提供血液和组织库，以及针对特定方案的 ciinicai 库。对于本次更新中提出的所有项目，核心将执行各种标准化、SOP 驱动的免疫监测测定。对于项目2，Core B还将制备自体树突状细胞疫苗。核心 B 将支持每个项目如下：项目 1 (Tarhini/Storkus) 核心 B 将支持项目 1 的目标 1a 和 lb，测试 ECOG 1609 试验中的循环细胞和血清生物标志物。核心 B 将评估宿主效应细胞和抑制细胞免疫反应。我们将进行多色流式细胞术来比较治疗前后的 PBMC，重点关注循环抑制细胞（Treg 和 MDSC）和抗原特异性效应和辅助 T 细胞，以及血清生物标志物。项目 2（Butterfield/Kirkwood）：Core 将通过自体 AdVTMM2 转导的树突状细胞疫苗的制造、表征和释放来支持目标 1（临床试验 #09-021）。 Core 将处理所有血液、白细胞分离术和肿瘤样本，并执行所有存储对于 Aim 2，Core 将执行许多标准化免疫反应测定。项目 3（Zarour/Ferrone）：核心将通过 PBMC 库和共享黑色素瘤抗原特异性 T 细胞的激活和扩增测试来支持该项目。项目 4（Falo/Geskin/Tawbi）核心 B 将为 CTCL 和黑色素瘤患者执行项目 4 中提出的系统免疫监测。这将包括血清、PBMC 和肿瘤样本库和测试，包括先天细胞和效应细胞分析。 Biospecimen Core B 将共同支持 SPORE 的组织库（所有项目）、标准化免疫监测（所有项目）和用于治疗的 cGMP 细胞产品生产（项目 2）等项目。核心 B 中生成的数据将在生物统计学核心 C 中进行分析，并与临床参数相关联。血液和组织库数据和库存链接到临床试验管理应用程序，并将成为由信息学核心 D 开发和管理的研究数据仓库的一部分。